Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) Trial.

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Robina Aerts, Maarten F Corsten, Julien De Greef, Astrid Demandt, Maya Hites, Sammy Huygens, Katrien Lagrou, Hanne Lamberink, Tom Lodewyck, Johan Maertens, Ine Moors, Laurens Nieuwenhuizen, Bart Rijnders, Alexander Schauwvlieghe, Sophie Servais, Elena van Leeuwen-Segarceanu

Ngôn ngữ: eng

Ký hiệu phân loại: 133.531 Sun

Thông tin xuất bản: United States : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 590589

Thêm vào giỏ Liên kết toàn văn

The IA-DUET study aimed to compare azole-echinocandin combination therapy with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.

Tạo bộ sưu tập với mã QR